VONTOBEL FINANCIAL PRODUCTS GMBH | Market Closed - Boerse Frankfurt Warrants 18:43:29 07/06/2024 BST | ||
| 100.4 EUR | -0.02% |
|
| Current month | +0.19% | ||
| 1 month | +0.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 100.4 | -0.02% |
| 06/06/24 | 100.5 | +0.17% |
| 05/06/24 | 100.3 | -0.07% |
| 04/06/24 | 100.4 | +0.06% |
| 03/06/24 | 100.3 | +0.05% |
Real-time Boerse Frankfurt Warrants
Last update June 07, 2024 at 06:43 pm
More quotesStatic data
| Product type | Aktienanleihen |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM8RPV |
| ISIN | DE000VM8RPV9 |
| Date issued | 24/01/2024 |
| Strike | 728.6 kr |
| Maturity | 26/01/2026 (597 Days) |
| Parity | 0.73 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | Beides |
| Currency | EUR |
Technical Indicators
| Highest since issue | 101.2 € |
|---|---|
| Lowest since issue | 99.08 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- Certificat
